Development of a new drug to overcome progressive MS - MS Research Australia

Development of a new drug to overcome progressive MS

Dr Steven Petratos

Monash University, VIC

| Better treatments | Neurobiology | Project | 2018 | Investigator Led Research |
SUPPORT PROJECTS WITH THIS RESEARCH FOCUS

Summary

Myelin is the protective coating around nerve fibres in the brain and spinal cord. In MS, the immune system mistakenly attacks the myelin. In progressive MS, there is a gradual increase in disability without periods of remission. This gradual loss of myelin may be the cause of progressive MS.

In previous studies, it was found that the molecule called MCT8 is lacking in some people with MS. This molecule is found in the cells that make myelin, called oligodendrocytes. Without sufficient amounts of MCT8, the oligodendrocytes die and do not produce myelin.

In this project, Dr Steven Petratos and his team will perform some pre-clinical studies to determine if a potential therapeutic is able to stop and potentially reverse the loss of myelin in the brain. This therapy may allow the oligodendrocytes to survive and produce myelin, allowing the body to repair itself. This research may lead to a new therapeutic option for people with progressive MS.

Updated: 11 January 2018

Updated: 05 January, 2018

Investigator

  • Dr Steven Petratos, Monash University, VIC

Co-investigator

  • Dr Kaylene Young, University of Tasmania, TAS

Grant Awarded

  • Project Grant

Total Funding

  • $70,000

Duration

  • 1 year over 2018

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search